Alpha Pro Tech Ltd. - Q1 2003 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2003. Alpha Pro Tech, Ltd. manufactures and distributes disposable masks, shields, shoe covers, apparel, and wound care products. The company serves medical, dental, industrial safety, and clean room markets, predominantly in the United States. The company is incorporated in Delaware with principal executive offices in Markham, Ontario, Canada.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Net Sales | $5,244,000 | $5,203,000 |
| Gross Margin | $2,726,000 (52.0%) | $2,425,000 (46.6%) |
| Net Income | $465,000 | $421,000 |
| Diluted EPS | $0.02 | $0.02 |
| Cash and Equivalents | $2,449,000 | $1,705,000 |
| Working Capital | $7,292,000 | N/A |
| Total Debt (Notes Payable) | $370,000 | N/A |
| Operating Cash Flow | ($62,000) | $805,000 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased slightly by 0.8% ($41,000) year-over-year. Growth was driven by the Pharmaceutical industry and a surge in demand for N-95 masks due to the SARS outbreak, offset by weakness in the Semiconductor clean room market.
- Margin Expansion: Gross margin improved significantly from 46.6% to 52.0%, driven by a decrease in Cost of Goods Sold (excluding depreciation) despite flat revenue.
- Expense Increase: Selling, General, and Administrative (SG&A) expenses rose 12.6% to $1.867 million, primarily due to increased payroll costs from expanding the sales and marketing team from 14 to 18 personnel.
- Cash Flow Shift: Operating cash flow turned negative ($62,000 used) compared to a positive $805,000 in the prior year, largely due to increased inventory levels ($622,000 increase) and accounts receivable.
- Share Repurchases: The company repurchased 290,000 shares for $274,000 during the quarter.
Outlook, Risks, and Management Commentary
- SARS Impact: Management anticipates a significant increase in demand for N-95 Particulate Respirator masks and other protective products for at least the next two quarters of 2003 due to the SARS outbreak.
- Market Outlook: Sales growth is expected in the Pharmaceutical sector. However, the Semiconductor market remains weak, with recovery not expected until late 2003.
- Liquidity: The company maintains a $4.076 million credit facility (including a $3.5 million line of credit). As of March 31, 2003, $2.466 million of the line of credit was unused. Management believes current cash and credit facilities are sufficient for working capital and planned capital expenditures.
- Capital Expenditures: The company expects to purchase an additional $250,000 of equipment in 2003.
- Accounting Standards: The company adopted SFAS 143 (Asset Retirement Obligations) and SFAS 148 (Stock-Based Compensation disclosures) but does not expect significant financial impact from these changes.
Investor Verification Checklist
- SARS Demand Sustainability: Verify the duration and volume of the SARS-related demand for N-95 masks to assess if Q2 and Q3 revenue projections are realistic.
- Inventory Build-up: Investigate the $622,000 increase in inventory to ensure it aligns with the anticipated SARS demand and does not signal future obsolescence risks.
- Semiconductor Recovery: Monitor the Semiconductor clean room market for signs of recovery, as this remains a drag on the Apparel division.
- SG&A Efficiency: Track whether the increased sales and marketing headcount (18 vs 14) yields the projected sales growth to justify the 12.6% expense increase.
- Cash Flow Reversal: Watch for the reversal of negative operating cash flow in subsequent quarters as inventory and receivables stabilize.